BLTC Research logo
From
THE GOOD DRUG GUIDE

".....Amineptine (Survector) is a clean-ish, (relatively) selective dopamine reuptake blocker. Higher doses promote dopamine release too. Amineptine is pro-sexual and liable occasionally to cause spontaneous orgasms. It is a mild but pleasant psychostimulant and a fast-acting mood-brightener.

        The compound was first synthesized by French pharmaceutical giant Servier. Licensed in France from 1978 under the brand name "Survector" and soon widely marketed abroad, amineptine is a clinically useful antidepressant. Unlike most other tricyclics, it doesn't impair libido or cognitive function.

        Amineptine has a small but non-negligible abuse-potential. Its enjoyable but short-lived psychostimulant effect should be distinguished in clinical practice from its sustained antidepressant action. Arguably all too many contemporary "antidepressants" lack abuse-potential not through superior design or clinical efficacy, but because they aren't any good. The widely prescribed selective serotonin reuptake inhibitors (SSRIs), for instance, don't reverse the diminished libido and lack of interest in sex characteristic of (many kinds of) depression. Instead, SSRIs exacerbate the problem.

        Unlike typical stimulants and other activating agents, amineptine may actually improve sleep architecture. Amineptine can be an especially valuable agent for melancholic, anhedonic and unmotivated people whose mood is sometimes worsened by SSRIs. Amineptine is also a useful agent in treating chronic "low grade" depression or dysthymia. There is little evidence of its value in anxious or agitated depression. Anxious depressives may do better on its chemical cousin, tianeptine (Stablon).

        Amineptine isn't marketed or licensed in Britain and America. In Europe, too, the medication has been driven onto the pharmaceutical grey market. This is because FDA pressure led to the withdrawal of amineptine's EC product-license early in 1999, causing substantial problems for patients and physicians alike. In early 2005, Servier ceased production of amineptine in Brazil. It is still available in some Uruguayan pharmacies or as a research chemical, but the world-wide famine persists. Amineptine is off-patent, but not cheap. Optimal dosage is variable; but typically 100mg-200mg per day. No exact substitute for amineptine is currently on offer or in prospect...."


Manufacture       Merck Manual       Search Medline

amineptine ( Survector ) : the smart tricyclic?

Refs
and further reading

Amineptine
tianeptine.com
BLTC Research
Online Pharmacies
Amineptine : sources
Amineptine : synthesis
Search amineptine.com

E-mail
Webmaster